According to the American Lung Association, the national five-year lung cancer survival rate is about 29.7 percent. The ...
The agency also granted traditional approval to later-line nivolumab indications for certain adults with the disease.
The U.S. Food and Drug Administration (FDA) on Friday approved Bristol Myers Squibb & Co.’s BMY Opdivo (nivolumab) with chemotherapy for untreated Hodgkin lymphoma, one of the most curable forms of ...
The FDA has approved the combination of nivolumab plus chemotherapy as first-line treatment for certain patients with stage III or IV classical Hodgkin lymphoma.The approval, for individuals aged 12 ...
Amini: From a radiation standpoint, this has changed the landscape of our field. A large proportion of my practice is stage IV disease, where patients who are on these excellent systemic therapies are ...
Benefit was maintained across MZL subtypes and subgroups, including splenic MZL, with particularly favorable 24-month outcomes among patients achieving complete response. Safety signals aligned with ...
In a study published today in Nature Medicine, researchers from the University of Oxford and the Muhimbili University of ...
In a study published in Nature Medicine, researchers from the University of Oxford and the Muhimbili University of Health and ...
A treatment regimen of penpulimab combined with rituximab, high-dose methotrexate, and cytarabine (Pen-RMA) achieved its primary endpoint in newly diagnosed primary central nervous system lymphoma ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results